EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland

Atte Vaden, Mari Lahelma, Lalli Nurmi, Eija Heikkilä iD, Hannu Vessari, Hanne Luoto, Tero Saukkonen, Leo Niskanen

Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 7814-7824

DOI: 10.1111/dom.70920 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 09.06.2026. Verfasst von Atte Vaden und 7 weiteren Autor:innen. Beteiligte Einrichtung: West-Northern Central Hospital, Department of Internal Medicine, Kemi, Finland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This Finnish nationwide retrospective 'real‐world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP‐1 receptor agonists in Finland. Materials and Methods Adults living with T2D ( n = 7249) who initiated oral semaglutide between April 1, 2021, and December 31, 2023, were identified from national registers and followed until June 30, 2024. Primary endpoints were changes in HbA1c and body weight from baseline to 182.5 and 365 days. Secondary endpoints included changes in LDL‐cholesterol, HDL‐cholesterol, total cholesterol, triglycerides, HDL/triglycerides ratio, and ALT.

Results

Of those initiating oral semaglutide, 65.8% remained on treatment at 180 days and 55.2% at 365 days. Among patients included in longitudinal trajectory modelling, mean HbA1c ( n = 2784) decreased from 7.9% to 6.8% at 182.5 days (95% CI: −1.20 to −1.04; p < 0.001) and to 6.9% at 365 days (95% CI: −1.18 to −0.95; p < 0.001). Mean body weight ( n = 832) declined from 106 to 100 kg at 182.5 days (95% CI: −7 to −5; p < 0.001) and to 98 kg at 365 days (95% CI: −10 to −6; p < 0.001). LDL‐cholesterol ( n = 1402), and triglycerides ( n = 975) were significantly reduced at 182.5 days with little further change at 365 days. Mean ALT ( n = 1762) declined from 50 to 42 U/L at 182.5 days (95% CI: −10 to −6, p < 0.001) and to 37 U/L at 365 days (; 95% CI: −16 to −10; p < 0.001). While weight at baseline was lower at patients aged at least 75 years, the changes in HbA1c and weight were similar compared to patients under 75 years of age.

Conclusion

Oral semaglutide significantly improves glycaemic and lipid control, body weight, and liver enzymes in adults living with T2D treated in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like PeptidesHumansSemaglutideFemaleRetrospective StudiesFinlandMaleMiddle AgedGlycated HemoglobinAgedAdministration, OralBlood GlucoseBody WeightAdultGlycemic Control

Stichwörter der Autor:innen

glycaemic controlliverreal‐world evidencesemaglutidetype 2 diabetesweight management

Substanzen

SemaglutideHypoglycemic AgentsGlucagon-Like PeptidesGlycated HemoglobinBlood Glucosehemoglobin A1c protein, human

Autor:innen und Institutionen

  • West-Northern Central Hospital, Department of Internal Medicine, Kemi, Finland.
  • Tesoma Welfare Alliance, Tampere, Finland.
  • Medical Center Mehiläinen, Tampere, Finland.
  • Nordic Healthcare Group, Helsinki, Finland.
  • Novo Nordisk Farma Oy, Espoo, Finland.
  • Faculty of Social Sciences, Health Sciences, Epidemiology, Tampere University, Tampere, Finland.

ORCID-Profile: Eija Heikkilä

Förderung

  • Novo Nordisk Pharma

Zitieren

APA

Vaden, A., Lahelma, M., Nurmi, L., Heikkilä, E., Vessari, H., Luoto, H., Saukkonen, T., & Niskanen, L. (2026). Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland. Diabetes, Obesity and Metabolism, 28(9), 7814-7824. https://doi.org/10.1111/dom.70920

Vancouver

Vaden A, Lahelma M, Nurmi L, Heikkilä E, Vessari H, Luoto H, et al. Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland. Diabetes, Obesity and Metabolism. 2026;28(9):7814-7824. doi:10.1111/dom.70920

BibTeX
@article{Vaden2026,
  author = {Vaden, Atte and Lahelma, Mari and Nurmi, Lalli and Heikkilä, Eija and Vessari, Hannu and Luoto, Hanne and Saukkonen, Tero and Niskanen, Leo},
  title = {Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {9},
  pages = {7814--7824},
  doi = {10.1111/dom.70920}
}
Kostenlos starten →